Genovis, a company that develops transfection technologies based on nanotechnology, completed the investment in SEQURNA, a biotechnology research company. Financial terms were not disclosed. "This strategic investment opens up for new product offerings to both existing and new customers, and facilitates the expansion into new application areas. We will utilize our distribution network to market and sell SEQURNA’s RNase inhibitors alongside our own catalogue of innovative tools for the biopharmaceutical and research industries," Genovis.